变化格局下HER2阳性乳腺癌的当前管理
本文综述了HER2阳性乳腺癌治疗的演变,指出转移性患者中位生存已从不足2年改善至长期生存超过5年成为常见。早期治疗的进步降低了复发率并改变了转移性疾病的临床格局,T-DXd展现出前所未有的疗效并正快速向更早治疗线推进,由此引出最佳序贯、毒性管理(尤其间质性肺病)及对其他HER2靶向治疗的影响等问题。
要点
- 转移性HER2阳性乳腺癌中位生存已从不足2年改善至长期生存超过5年常见。
- 早期治疗进步降低复发率,新发转移比例上升而靶向治疗后复发比例下降。
- T-DXd疗效前所未有,正快速向转移和治愈性场景的更早治疗线推进。
核心结论
- HER2阳性乳腺癌治疗经三代HER2靶向药物演变后预后显著改善,T-DXd正快速前移并重塑治疗格局。
研究设计与样本
- 本文为综述,总结HER2靶向治疗的演变并讨论T-DXd早期治疗时代各疾病阶段的管理策略。
主要发现
- 转移性HER2阳性乳腺癌既往中位生存不足2年,目前长期生存超过5年已变得常见。
- 早期治疗的平行进步大幅降低复发率并改变转移性疾病格局,新发转移患者比例上升。
- 单克隆抗体、酪氨酸激酶抑制剂和抗体药物偶联物 successive generations 推动了上述改善。
- T-DXd展现出前所未有的疗效,正快速向转移性和治愈性场景的更早治疗线推进。
临床怎么用
- T-DXd前移后需关注最佳序贯安排、毒性管理(尤其间质性肺病)及对其他HER2靶向治疗的下游影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over the past three decades, the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer has undergone a remarkable transformation. Once associated with poor outcomes and a median survival of <2 years in the metastatic setting, HER2-positive metastatic breast cancer is at present increasingly managed for years, with long-term survival beyond 5 years becoming common. Parallel advances in early-stage therapy have substantially reduced recurrence rates and altered the clinical landscape of metastatic disease, with a growing proportion of patients currently presenting with de novo metastatic disease rather than relapse after prior HER2-directed treatment. These improvements have been driven by successive generations of HER2-targeted therapies, including monoclonal antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates. Most recently, trastuzumab deruxtecan (T-DXd) has demonstrated unprecedented efficacy and is rapidly moving earlier in treatment algorithms across both metastatic and curative-intent settings. This shift raises important questions regarding optimal sequencing, toxicity management-particularly for interstitial lung disease-and the downstream implications for other HER2-directed therapies. In this review, we summarize the evolution of HER2-targeted therapy and discuss strategies for managing HER2-positive breast cancer across disease stages in the era of earlier treatment with T-DXd.
引用
- Lipsyc-Sharf M, Hurvitz SA. Current Management of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in a Changing Landscape. J Clin Oncol. 2026. PMID: 42441937. doi:10.1200/JCO-26-00672
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。